Patients with severe graft-versus-host disease (GVHD) requiring intensive immunosuppression are at high risk of invasive mould infections (IMI). Prophylaxis with an active, oral antifungal agents with reliable absorption in this context is desirable. A total of 44 patients at high risk of post-engraftment IMI received itraconazole solution 2.5 mg/kg b.d. as prophylaxis. Two of the first nine patients, in whom bioavailability was compromised due to significant vomiting and/or diarrhoea, died of probable or proven invasive aspergillus. None of the subsequent 35 patients, some of whom had severe gut GVHD and who received liposomal amphotericin B prophylaxis until itraconazole was reliably tolerated and absorbed, developed IMI. The overall incidence of IMI was substantially lower than in historical controls. Itraconazole was generally well tolerated, with five patients (11%) ceasing the drug due to intolerance or disturbed liver function. Targeted prophylaxis with oral or parenteral antifungal agents in high-risk allograft recipients appears to be effective in reducing the incidence of IMI.
GVHD
Invasive mould infections (IMI), particularly with aspergillus species, occur in up to 11% of patients after allogeneic BMT and may be increasing in incidence due to more invasive transplantation procedures in higher risk patients. 1 Characteristically, there is a bimodal pattern of IMI: an early peak during the initial period of neutropenia after conditioning and a late peak around 2-5 months post transplant, [2] [3] [4] the latter now comprising the majority of infections. Risk factors for later onset IMI include T-cell depletion, graft-versus-host disease (GVHD), use of highdose corticosteroids, CMV disease and neutropenia. 2, 3, 5, 6 Risk factors for IMI and its incidence appear similar after nonmyeloablative conditioning. 7 Corticosteroids contribute to the risk of IMI independently of GVHD due to complex immunobiological dysregulatory effects; 8 both the duration and dose of corticosteroids are important. 2, 9, 10 In our institution, the overall incidence of IMI in allograft recipients from 1991 to 1998 was 8%, 11 rising to 20% in those with grades III-IV acute GVHD. 12 An analysis of risk factors for post-engraftment IMI identified prolonged (42 weeks) use of 40.25 mg/kg/day of prednisolone or equivalent corticosteroid as a major risk factor. 12 In order to reduce this incidence, in 1998, our unit examined available prophylactic fungal strategies. Various amphotericin B-based approaches such as low-dose IV 6, 13 or inhaled 14 amphotericin B or liposomal amphotericin B 15 had been examined as prophylaxis with either negative or inconclusive results. Important problems with these strategies included the high cost of liposomal amphotericin B, the impracticality of prolonged parenteral delivery in the outpatient setting and renal toxicity. Key features of an ideal strategy included availability of an oral preparation with reliable and good bioavailability, activity against aspergillus and sufficient tolerability to enable administration for prolonged periods. Itraconazole capsules had activity in the treatment of invasive aspergillosis 16 and had been used as prophylaxis in high-risk patients with variable results. [17] [18] [19] [20] However, the bioavailability of itraconazole in capsule form was unpredictable between and within patients, 21 particularly if concomitant antacids were used. A new cyclodextrin-based oral itraconazole solution had recently become available. This preparation was characterised by enhanced bioavailability (approximately 50% better compared with capsule formulation), more consistent absorption in patients with severe mucositis and a low incidence of adverse events. 22 We therefore initiated an open-label, single-arm study of oral itraconazole solution as prophylaxis in allograft patients at high risk for post-engraftment IMI. The aims of the study were to assess the tolerability and bioavailability of this preparation and its efficacy in preventing IMI.
Study design

Eligibility
Allogeneic BMT recipients treated with curative intent and capable of giving informed consent with either:
1. severe GVHD defined as requiring at least one or more of the following: (i) prolonged (43weeks) high-dose prednisolone (X50 mg/day), (ii) treatment with antithymocyte globulin (ATG) or (iii) treatment with repeated courses of high-dose prednisolone OR 2. moderate GVHD requiring ongoing immunosuppression (but less than severe GVHD) and with colonisation by aspergillus in sputum or nasal swab in the absence of radiologic evidence of IMI on high-resolution CT scan (HRCT) of chest or CT scan of sinuses. This criterion, included as the isolation of aspergillus from respiratory secretions in an immunocompromised patient, is highly predictive of subsequent invasive infection. 23 As will be discussed later, the protocol was modified after our experience with the first nine patients to exclude those with active severe gut GVHD with vomiting and diarrhoea.
Investigations
Baseline investigations consisted of a chest X-ray, nasal swab, sputum culture if available, standard biochemistry and a cyclosporin level. An HRCT chest was performed if the chest X-ray demonstrated abnormalities other than basal atelectasis, with subsequent bronchoscopy and lavage (BAL), if appropriate. A sinus CT scan was performed in patients with positive nasal swabs. Patients with a baseline diagnosis of proven or probably IMI were not enrolled. Subsequent routine tests included a chest X-ray every 2-3 weeks with a HRCT chest if abnormalities developed or progressed, biochemical screen every 2 weeks, cyclosporin levels with any alteration in itraconazole dose and itraconazole levels as outlined subsequently. A HRCT chest was also performed in any patient with symptoms (eg cough, haemoptysis, unexplained fever, etc) consistent with an IMI; abnormalities consistent with infection of any type were investigated with a subsequent BAL.
Drug therapy
Oral itraconazole in a hydroxypropyl-B-cyclodextrin solution (10 mg/ml) was given at a dose of 2.5 mg/kg b.d. on an empty stomach. Where feasible, trough and/or 2-4 h postdose levels were taken, no earlier than 2 weeks after commencement of the drug. Serum itraconazole levels were measured by high-performance liquid chromatography and although itraconazole and hydroxy-itraconazole levels were measured, only itraconazole levels are reported here. At the time the protocol was written, values greater than 350 ng/ ml were regarded as therapeutic. 24 In patients with levels below this, the protocol allowed for dose increases in increments of 1 mg/kg b.d. with repeat levels 10-15 days thereafter. As itraconazole may increase cyclosporin levels by inhibiting cytochrome P450, 25 trough serum cyclosporin levels were regularly monitored and the cyclosporin dose was reduced if the level exceeded 500ng/ml or toxicity occurred.
Itraconazole was discontinued if:
(i) the prednisolone dose fell below 10 mg/day; (ii) aspergillus colonisation resolved, as defined by negative results of microscopy and culture in at least two samples from the original site after a minimum of 4 weeks of therapy; (iii) gastrointestinal side effects attributable to itraconazole were not tolerable despite dose reduction. (iv) progressive hepatic dysfunction (in general, liver enzymes 43 times the upper limit of normal) occurred, which was not attributable to other causes; (v) proven or probable IMI was diagnosed.
After the first nine patients were enrolled, it became apparent that bioavailability was compromised in patients with severe active gut GVHD. As no intravenous formulation of itraconazole was available then, subsequently all such patients received liposomal amphotericin B 100 mg i.v. three times per week as prophylaxis until oral itraconazole could be commenced (new patients were only enrolled at this time) or resumed (for patients already enrolled on study) and levels were therapeutic. Patients with IMI were taken off the study and treated with amphotericin B or liposomal amphotericin B.
Statistics
The main study end point was the incidence of probable or proven IMI. The initial study protocol allowed for the enrolment of 10 patients with the undertaking that if IMI occurred in X3 patients, the study would be revised or terminated. Two of the first nine patients developed IMI, both in the context of severe gut GVHD and assumed or documented subtherapeutic itraconazole levels. The protocol was, therefore, revised to exclude patients with severe active gut GVHD and diarrhoea. The study was planned to continue, provided breakthrough IMI occurred in p2 patients in all subsequent consecutive cohorts of 10 patients. Ultimately, 44 patients were enrolled on the study.
The following data were collected: itraconazole dosage and levels, WHO grades 2-4 toxicities, serial biochemistry measurements and cyclosporin levels, concomitant medication, results of any relevant radiological or microbiological investigations, status of GVHD, including documentation of gastrointestinal and hepatic involvement, and overall clinical status.
The Pearson w 2 -test was used to analyse the association between the presence or absence of severe GVHD and subtherapeutic or therapeutic itraconazole levels. The Jonckhere-Terpstra test was used to evaluate the relationship between duration of itraconazole administration and drug levels. All statistical tests were completed using StatXact 5.
Definitions
IMI was defined as proven, probable or possible using recently published host, microbiological and clinical criteria, 26 and was considered to have occurred on study if it occurred during itraconazole prophylaxis or within 2 weeks of its cessation.
Supportive care and GVHD treatment
Allograft recipients were infused with T-replete stem cells, and were managed predominantly in positive pressure, high-efficiency particulate air (HEPA)-filtered rooms as inpatients. However, intensive care admissions, endoscopic procedures and radiological investigations other than chest X-rays took place in areas of the hospital that were not HEPA filtered. Patients not eligible to receive itraconazole were given fluconazole prophylaxis 400 mg/day until 3 months post transplant 27 and fluconazole 200 mg/day thereafter if the daily prednisolone dose was X10 mg.
Treatment of moderate to severe GVHD consisted of optimisation of cyclosporin levels and commencement of i.v. methylprednisolone 1-2 mg/kg/day or an equivalent oral prednisolone dose. Steroid-resistant GVHD, most typically gastrointestinal, was managed with ongoing steroids, i.v. tacrolimus and ATG; oral budesonide was added in the absence of vomiting. Infliximab, recently associated with IMI in this context, 28 was not used.
Results Table 1 details the demographics of the 44 patients who were enrolled in the study. These patients represented 21% of the total number of patients (205) who underwent allografting during the study period (December 1997-November 2002) and survived beyond engraftment. Most patients were transplanted for acute leukaemia (14) , chronic myeloid leukaemia (11) or lymphoma (9) . A total of 24 patients had advanced disease, that is, adult leukaemia or lymphoma, which was either primary refractory or chronic myeloid leukaemia beyond chronic phase.
Baseline investigations
Baseline chest X-ray results were available for 40 patients. In all, 10 were noted to display minor abnormalities, chiefly basal atelectasis and patchy opacities. Baseline HRCT chest was performed in eight patients with abnormal CXRs and/ or colonisation. These showed the following: minor opacities (four), extensive opacities without nodules or cavitation (one), basal atelectasis (one), a solitary 3 mm nodule without cavitation, halo or air crescent (one) and normal (one).
The results of baseline nasal swabs were available for 37 patients. Three grew Aspergillus fumigatus. Three of four patients with productive sputum at the baseline cultured Aspergillus species. (A. fumigatus in two, A. tereus in one). These patients with either nasal swab or sputum growth of fungus represent the six patients who fulfilled the study criterion for colonisation; the median prednisolone dose at entry of this group was 30 mg (range 15-75 mg). Serum itraconazole levels were available on at least one occasion in 33 patients. Table 2 depicts trough levels at various time points in relation to dose. There was no significant difference between levels at different time points. Table 3 depicts the relationship between therapeutic levels and severe active gut GVHD, the latter defined, for this purpose, as requiring hospitalisation for management of vomiting and/or diarrhoea. Patients with severe GVHD were more likely to have subtherapeutic levels than those with moderate GVHD (P ¼ 0.005). Of the six patients with severe GVHD and subtherapeutic levels, all had grade III or IV gut involvement. The median duration of itraconazole administration in these patients was 56 (range 27-135) days.
Itraconazole dose, levels and adjustments
Of the 44 patients, 27 underwent a total of 54 dose adjustments or interruptions. These occurred for the following reasons: miscellaneous management issues (eg intubation, relapse, etc.) for 29, gastrointestinal toxicity for six, hepatic toxicity for two, high cyclosporin levels for two, low levels for three and undocumented reasons for five. Dose reduction for levels 42000 ng/ml, without specific toxicity, occurred in seven instances.
A total of 39 patients were receiving full therapeutic cyclosporin doses at the time itraconazole was commenced. Of the 28 who received itraconazole for more than 2 weeks, 14 required a cyclosporin dose reduction specifically due to high trough levels or toxicity, predominantly an increase in creatinine. In most of the other patients, cyclosporin dose was reduced as part of a planned taper for resolving GVHD.
Hepatic toxicity
One and seven patients, respectively, had alkaline phosphatase (AP) and alanine transferase (ALT) levels more than three times the upper limit of normal (43 ULN) at study entry. An additional four and 10 patients, respectively, developed AP or ALT values 43 ULN during the study. Itraconazole was ceased in two patients due to increasingly abnormal liver function. Data for these two patients are as follows: Patient 1: ALT 228 IU/l at baseline (normal o55 IU/l), 679 IU/l at day 20, itraconazole levels day 22: trough 1724 ng/ml, post 3191 ng/ml. Itraconazole was then ceased and the ALT normalised 3 weeks later. Patient 2: AP 92 IU/l at baseline (normal o120 IU/L), 447 IU/l at day 37 (ALT normal), itraconazole then ceased (no levels), 134 IU/l 2 months post-cessation.
Gastrointestinal toxicity
Seven patients had significant nausea, vomiting and/or diarrhoea, which was attributed to itraconazole. This required dose reduction in four and cessation in three patients, respectively. Five of the patients had itraconazole levels within 2 weeks of onset of gastrointestinal symptoms: two had levels o250 ng/ml and two had levels 41000 ng/ ml.
Off study
Breakthrough IMI developed in two patients who were then withdrawn. In all, 14 additional patients withdrew from the study prematurely because of: disease relapse or progression (seven), gastrointestinal or hepatic toxicity (five), fatal infection (one) and terminal GVHD (one). A total of 28 patients completed the study and ceased itraconazole once the prednisolone dose fell below 10 mg/ day (23) or fungal colonisation had resolved (five).
Liposomal amphotericin B
Subsequent to the ninth patient enrolled on study, 11 patients with active gut GVHD prior to study entry received prophylactic liposomal amphotericin B 100 mg i.v. three times per week until resolution of gastrointestinal symptoms. Patients were then enrolled for the study and itraconazole was commenced; liposomal amphotericin B was continued until itraconazole was tolerated in full dose for 2 weeks. Four recent patients also received liposomal amphotericin B during a short period while on study when they were either intolerant of oral medication or itraconazole levels were low.
Invasive mould infection
Probable or proven IMI occurred in two patients (4%) while receiving itraconazole or within 2 weeks of its discontinuation.
Study patient no. 1. Itraconazole was commenced in the context of multisystem GVHD with moderate to severe diarrhoea. The patient refused to stay in a HEPA-filtered room. A cavitating pulmonary nodule was noted on a chest X-ray on day 20 and itraconazole was replaced by liposomal amphotericin B. After 2 weeks, brain magnetic resonance imaging (MRI) demonstrated a ring-enhancing lesion consistent with fungus. No itraconazole levels were obtained. At post-mortem, angioinvasive pulmonary and cerebral fungal hyphae consistent with invasive A. fumigatus was identified.
Study patient no. 4. Itraconazole was commenced in the context of severe gut GVHD with profuse diarrhoea. HRCT chest at baseline showed extensive lower lobe opacities without radiological features of fungal infection; fungus was not identified on BAL. A repeat CT after 11 days of therapy was substantially improved. Itraconazole was replaced after 4 weeks with liposomal amphotericin B due to subtherapeutic levels (156 nmol/l) and ongoing diarrhoea. After 2 weeks, the patient developed progressive pulmonary failure, and BAL at this time grew A. fumigatus. An autopsy was not performed.
Five other patients died while on study. The causes of death were: influenza A respiratory failure, multiorgan 
Discussion
This pilot study suggests that itraconazole solution is an effective prophylaxis in selected patients at high risk of IMI in the post-engraftment period. A clear exception is patients with severe active gut GVHD in whom itraconazole absorption is badly compromised. IMI developed in 2/44 patients (4%) overall, but notably in none of the last 35 patients in whom therapeutic levels were either documented or assumed in the absence of significant diarrhoea. Importantly, some of the later patients in our study received prophylactic liposomal amphotericin until itraconazole could be reliably absorbed. This low incidence contrasts with the previous 20% incidence of IMI documented in patients at our centre with grades III-IV GVHD, who received identical support care measures other than prophylaxis with fluconazole instead of itraconazole. 12 While more patients in our study received nonmyeloablative conditioning than in our historical controls, the Seattle group have reported that the incidence of late-onset IMI is not influenced by the type of conditioning regimen and is around 40% in patients with grades III-IV acute GVHD receiving fluconazole prophylaxis after reduced intensity allografts. 29 These results are consistent with those of other recently published randomised studies, summarised in Table 4 , which confirm the effectiveness of prophylactic itraconazole solution in allograft recipients and neutropenic haematology patients. [30] [31] [32] A meta-analysis in patients with haematological malignancies emphasised the importance of using the cyclodextrin solution for oral administration, as efficacy was clearly associated with a higher bioavailable dose. 30 This analysis included the two studies restricted to allograft patients in which itraconazole and fluconazole prophylaxis were compared. The first, in which itraconazole was initially given i.v. as a loading dose in order to rapidly obtain therapeutic levels, 33 demonstrated superiority over fluconazole in reducing IMI. Subsequently, this group has routinely used itraconazole prophylaxis postallograft until day 100 or longer in patients requiring steroids for GVHD. None of the 53 high-risk patients who managed in this way have developed invasive aspergillus. 34 The second study, using either i.v. or oral itraconazole, failed to demonstrate a reduction in invasive fungal infections (candidemia and moulds) with an intention to treat analysis, perhaps due to excessive toxicity and drug discontinuation in the itraconazole arm as high oral drug doses (2.5 mg/kg three times daily) were given 32 and itraconazole increased exposure to toxic metabolites of cyclophosphamide. 35 The risk of IMI, particularly invasive aspergillosis was, however, significantly lower in patients who received itraconazole.
In both these studies, patients at both low and high risk of IMI were enrolled and prophylaxis was provided from the time of conditioning to days 100-180 post transplant. Our approach differed in that we targeted prophylaxis to patients identified to be at high risk of developing IMI, irrespective of the time post-engraftment. This approach may avoid unnecessary exposure to itraconazole and excessive toxicity, especially in the early peritransplant period where interactions with cytotoxic agents are problematic. 35 Of note, IMI was not seen in any of the other 161 'low-risk' patients transplanted during this time who did not receive itraconazole prophylaxis. The ability to target antifungal agents to patients during highest risk may be improved by surveillance chest CT scans 36 and newer diagnostic tests such as the galactomannan assay and aspergillus polymerase chain reaction 37, 38 Well-recognised side effects of itraconazole include reversible increases in hepatic enzymes, nausea, abdominal pain and constipation. These symptoms are common in Table 4 Randomised studies of itraconazole prophylaxis in haematology allograft recipients due to causes other than itraconazole, particularly GVHD and other medications. Five patients (11%) in our study had significant symptoms or biochemical abnormalities attributable to itraconazole, and they rapidly resolved upon cessation of the drug. This figure is substantially lower than the 36% discontinuation rate due to toxicity reported by the Seattle group, 32 and suggests that lower doses which still result in therapeutic levels may be most effective on the whole. Of note, however, the optimal minimum therapeutic plasma itraconazole level for prophylaxis against intensive fungi is not clearly established, with values of 250, 350, 500 and 1000 ng/ml suggested in the literature. 20, [39] [40] [41] In our experience, itraconazole levels were 4500 ng/ml in the vast majority of patients without severe gut GVHD and hence may only be clinically indicated in patients with vomiting or diarrhoea or in whom compliance is questionable. Conversely, the value of monitoring levels for toxicity in these complex patients is unclear.
The majority of patients planned to receive ongoing fulldose cyclosporin who reliably absorbed itraconazole required a dose reduction due to increased cyclosporin levels or toxicity. Careful monitoring for cyclosporin toxicity is, therefore, needed when itraconazole is commenced.
Itraconazole has also been associated with congestive heart failure; 42 while routine assessment of ventricular function was not performed in this protocol, no patient developed clinically overt cardiac failure while on study.
A potential concern with long-term itraconazole prophylaxis is the development of aspergillus species resistant to azoles as a class 43 or the emergence of previously less common fungi such as Scedosporium prolificans, which are often azole resistant. 44 We do not have antifungal susceptibility testing on the two aspergillus isolates obtained while on prophylaxis, but in the Seattle study none of the 25 aspergillus isolates recovered from either itraconazole or fluconazole recipients had itraconazole MICs 41.0 mg/ml.
32
In conclusion, oral itraconazole solution appears to be an effective and generally well-tolerated antifungal prophylaxis in selected allograft recipients at high risk of IMI post-engraftment. Given the high morbidity and mortality of IMI in these patients and the substantial expense of treating an established IMI, prophylaxis with oral itraconazole is likely to be cost-effective. Parenteral administration of an antifungal agent, however, is required in patients with vomiting and/or diarrhoea, which may compromise absorption and result in subtherapeutic serum levels. Ongoing vigilance for the emergence of triazole-resistant fungi in severely immunocompromised patients on longterm antifungal prophylaxis is recommended. Targeting prophylaxis to identified high-risk patients for only the duration of risk is one approach to reducing unnecessary antifungal exposure and toxicity.
